Skip to main content
Clinical Trials/KCT0007311
KCT0007311
Recruiting
未知

Changes in anti-SARS-CoV-2 antibody levels in response to COVID-19 vaccine in patients with inflammatory bowel disease

Keimyung University Dongsan Hospital0 sites200 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the digestive system
Sponsor
Keimyung University Dongsan Hospital
Enrollment
200
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Keimyung University Dongsan Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who will receive or have received a SARS\-CoV\-2 booster vaccine among IBD patients aged 20 to 80 years
  • 2\. Crohn's disease or ulcerative colitis patients who taking at least one of agents among 5\-aminosalycylic acid (ASA), immunomodulatory agents, and biological agents (infliximab, vedolizumab, ustekinumab etc)
  • 3\. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research

Exclusion Criteria

  • 1\. Those who have passed the booster vaccination more than 12 months ago
  • 2\. Those who have been diagnosed with IBD and have used IBD medications for less 3 months
  • 3\. Those who have had surgery within 3 months at the time of registration
  • 4\. Those who do not agree to participate in the research

Outcomes

Primary Outcomes

Not specified

Similar Trials